Data from the Washington University study showed that the therapy reduced the amount of virus detected in samples of all Omicron subvariants tested in the lungs of mice, the London-based drugmaker said Monday.
AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 subvariant, in an independent lab study.
Data from the Washington University study showed that the therapy reduced the amount of virus detected in samples of all Omicron subvariants tested in the lungs of mice, the London-based drugmaker said Monday. The research has yet to be peer-reviewed.
The therapy, Evusheld, was tested against the BA.1, BA.1.1 and BA.2 subvariants of Omicron and was also shown to limit inflammation in the lungs.” The findings further support that Evusheld is a potentially important option to help protect. vulnerable patients, such as the immunocompromised, who could have poor outcomes if they became infected with COVID-19,” said senior AstraZeneca executive John Perez.
The World Health Organization said last week that numbers showing a global rise in COVID-19 cases could herald a much bigger problem as the Omicron and BA.2 variants proliferate amid easing of restrictions and testing. Vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, but Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in the event of an infection.
The results come after Britain approved the therapy last week for preventing infections in adults with poor immune responses. Evusheld is currently under review in Europe and is approved in the United States.
This post AstraZeneca COVID drug neutralizes Omicron subvariants in study was original published at “https://www.financialexpress.com/lifestyle/health/astrazeneca-covid-drug-neutralizes-omicron-sub-variants-in-study/2466577/”